The Latest Cardiac and Vascular News
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, presented positive 2-year clinical results from its multicenter clinical trial for BackBeat® Cardiac Neuromodulation Therapy (CNT) at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San […]
SANTA CLARA, Calif., Sept. 25, 2018 /PRNewswire/ — Based on its recent analysis of the North American heart-on-a-chip market, Frost & Sullivan recognizes TARA Biosystems with the 2018 North American Technology Innovation Award for its trailblazing Biowire™ II heart-on-a-chip platform. This solution produces mature, engineered, human cardiac tissues and demonstrates promise as a valuable […]
SAN DIEGO and SAN CARLOS, Calif., Sept. 24, 2018 /PRNewswire/ — BioCardia®, Inc. (OTC :BCDA ), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that positive data from two studies of its investigational CardiAMP stem cell therapy were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference. CardiAMP cell therapy […]
BURLINGTON, Mass.–(BUSINESS WIRE)–Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, presented late-breaking clinical trial results for its landmark Lipid-Rich Plaque (LRP) Study today at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. Cardiovascular disease remains the number one cause […]
HANGZHOU, China, CAESAREA, Israel, TAMPA, Florida — September 25, 2018— Venus Medtech (Hangzhou) Inc., the preeminent Chinese transcatheter heart valve company, today announced it has signed an agreement to acquire Keystone Heart Ltd., a privately-held medical device company and makers of TriGUARD 3™. The acquisition gives Venus Medtech international rights to […]
OR YEHUDA, Israel, Sept. 20, 2018 /PRNewswire/ — Cardiovalve announced today that it has commenced the AHEAD USmulticenter study (U.S. Early Feasibility Study of High Surgical Risk Patients with Severe Mitral Regurgitation Treated with the Cardiovalve Transfemoral Mitral Valve System). AHEAD US trial recruitment will start in early Q4 2018. The primary endpoint of the […]
BLOOMINGTON, Ind.–(BUSINESS WIRE)–Cook Medical announced that a new 5 mm diameter version of Zilver® PTX® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths available up to 140 mm that is indicated to treat vessels as small as 4mm in diameter. The range […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced positive clinical data from the company’s recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch® Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation […]
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 24, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), announced today topline results from the Vascepa® cardiovascular (CV) outcomes trial, REDUCE-IT™, a global study of 8,179 statin-treated adults with elevated CV risk. REDUCE-IT met its primary endpoint demonstrating an approximately 25% relative risk reduction, to […]
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018, at 10:05 a.m. […]
